Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, single centre Phase I study of the safety and tolerability of PG545 in patients with advanced solid tumours

Next Previous
X
Search
Trial Profile

An open-label, single centre Phase I study of the safety and tolerability of PG545 in patients with advanced solid tumours

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pixatimod (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions

    • Most Recent Events

    • 17 Aug 2012 New source identified and integrated (Australian New Zealand Clinical Trials Registry, ACTRN12611000016932).
    • 01 Aug 2012 Status changed from recruiting to discontinued according to a ClinicalTrials.gov record.
    • 20 Sep 2011 According to a Progen Pharmaceuticals media release, company has halted patient recruitment and will formally close the current PG545-101 study once the current cohort of patients is complete.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top